Global Idiopathic Pulmonary Fibrosis Market - 2023-2030

Market Overview

The Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,614.3 million by 2030. The global idiopathic pulmonary fibrosis market is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030). The key market trend is the increasing demand for strong pipeline drugs.

For instance, in March 2022, Blade Therapeutics announced the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause characterized by scarring of the lung parenchyma. It is an age-related disorder and the mechanisms of fibrosis in IPF remain elusive, with favored concepts of disease pathogenesis involving recurrent micro-injuries to a genetically predisposed alveolar epithelium followed by an aberrant reparative response characterized by excessive collagen deposition.

The global idiopathic pulmonary fibrosis market is driven by factors such as the increasing clinical trials of IPF drugs, the rising aging population, the availability of approved therapies, the growing pipeline and investigational drugs, rising awareness & early diagnosis, and advancements in research techniques.

For instance, in May 2023, Bristol Myers Squibb, a global biopharmaceutical company announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis. The study showed that twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 62% compared to placebo.

Market Dynamics

Availability of Approved Therapies

The availability of approved therapies is the major factor driving the market share during the forecast period. Approved IPF therapies, such as pirfenidone and nintedanib, have been shown to slow disease progression, preserve lung function, and reduce acute exacerbations. These medications target the underlying fibrotic processes in the lungs, providing a disease-modifying approach. The availability of these therapies has revolutionized IPF management, allowing healthcare providers to offer more effective and targeted treatment strategies.

For instance, in July 2022, PureTech initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). The active agent in LYT-100, called deupirfenidone, is a chemically-modified version of the approved IPF treatment Esbriet (pirfenidone) marketed by Genentech.

Limited Treatment Options and Side Effects of the Treatment

While there are approved therapies for IPF, the number of available treatment options remains limited. Pirfenidone and nintedanib are the mainstays of treatment, but some patients may not respond adequately or may experience intolerable side effects. The lack of alternative treatment options hampers market growth as patients and healthcare providers seek more diverse and effective therapies.

The available IPF treatments, such as pirfenidone and nintedanib, are associated with side effects that can be challenging for some patients. These side effects may include gastrointestinal symptoms, liver abnormalities, skin rashes, and others. The presence of side effects can lead to treatment discontinuation or reluctance to initiate therapy, which can limit market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a profound impact on the healthcare industry, including the idiopathic pulmonary fibrosis market. The available IPF treatments, such as pirfenidone and nintedanib, are associated with side effects that can be challenging for some patients. These side effects may include gastrointestinal symptoms, liver abnormalities, skin rashes, and others. The presence of side effects can lead to treatment discontinuation or reluctance to initiate therapy, which can limit market growth.

Clinical trials for IPF treatments and therapies were also affected by the pandemic. Many trials were temporarily halted or delayed due to safety concerns, limited resources, and difficulties in patient recruitment. The disruption in clinical trials slowed down the progress of potential new treatments and extended the timeline for their development.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the idiopathic pulmonary fibrosis market. The conflict and its aftermath can strain the healthcare infrastructure and research capabilities. Diverted resources, destruction of infrastructure, and brain drain could hinder the capacity for research and development, clinical trials, and access to specialized IPF care. This can slow down advancements in IPF treatment options and limit the availability of cutting-edge therapies.

The conflict and its consequences can divert attention and resources away from chronic diseases like IPF. In times of crisis, healthcare systems often prioritize immediate health needs, emergency response, and acute care services. This shift in focus may result in reduced attention to the management and research of chronic conditions like IPF.

Segment Analysis

The global idiopathic pulmonary fibrosis market is segmented based on treatment, end-user, and region.

Based on Treatment, the Drugs Segment is Expected to Dominate the Market Share

The market for drugs segment held 45.3% of the global idiopathic pulmonary fibrosis market share in 2022. The drugs segment continues to see significant research and development activities. Pharmaceutical companies are investing in the development of novel drug candidates that target different aspects of IPF pathophysiology. This ongoing innovation in drug development further strengthens the prominence of the drugs segment in the IPF market.

For instance, in October 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced that the first U.S. patient enrolled in FIBRONEER IPF drug, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).

Geographical Analysis

North America Holds the Largest Market Share Due to the High Disease Burden and Availability of Approved Therapies

North America held 40.2% market share for the idiopathic pulmonary fibrosis market in 2022 due to the high disease burden and availability of approved therapies. North America, particularly the United States, has a high prevalence of IPF compared to other regions. The region's aging population, environmental factors, and lifestyle contribute to the higher disease burden. The significant number of IPF patients in North America drives the demand for IPF treatments and contributes to the region's market dominance.

North America has been at the forefront of research and development in IPF treatment. The region has witnessed early approvals of key therapies for IPF, including pirfenidone and nintedanib. The availability of these approved therapies in North America has significantly contributed to the market growth, as patients have access to effective treatment options.

Competitive Landscape

The major global players in the market include: Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.

Why Purchase the Report?

• To visualize the global idiopathic pulmonary fibrosis market segmentation based on treatment, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of idiopathic pulmonary fibrosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global idiopathic pulmonary fibrosis market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies